Other research have found in subcutaneous tumor of mice injected with LP07 adenocarcinoma cells and then treated with CD19 monoclonal antibodies, compared to non-treated cancer mice, in tumors of monoclonal-treated animals, tumor area and weight and ki-67 were significantly reduced, which implied that CD19 seemed to play a protumoral role in LUAD. Here, CD19 is linked to adenocarcinoma.